SCHEMBL9962998

SCHEMBL9962998

C#CCC[C@@H](C(=O)O)[C@H](C)c1ccc(Cl)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.40
LMNA P02545 1/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
ALDH1A1 P00352 1/20 0.34
FFAR1 O14842 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP3A4 P08684 3/20 0.32
CYP2D6 P10635 3/20 0.32
SLC6A2 P23975 3/20 0.32
SLC6A4 P31645 3/20 0.32
SLC6A3 Q01959 3/20 0.32
KCNH2 Q12809 1/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
MEN1 O00255 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1155853 0.80 AKR1C3 (0.33) NAPRTAKR1C3AKR1C2ALDH1A1
SCHEMBL1155855 0.80 AKR1C3 (0.33) NAPRTAKR1C3AKR1C2ALDH1A1
SCHEMBL11964096 0.77 MME (0.47) CYP2D6MEN1KMT2A
SCHEMBL9962999 0.75 IDH1 (0.37) LMNAMAPT
SCHEMBL31420077 0.72 NAPRT (0.48) NAPRTLMNAAKR1C3AKR1C2POLB
SCHEMBL1747676 0.72 NAPRT (0.48) NAPRTLMNAAKR1C3AKR1C2POLB
SCHEMBL18017404 0.71
SCHEMBL16619533 0.71 CYP2C9 (0.38) LMNAPOLBFFAR1CYP3A4CYP2D6
SCHEMBL16619531 0.71 CYP2C9 (0.38) LMNAPOLBFFAR1CYP3A4CYP2D6
SCHEMBL5163504 0.71 AKR1C3 (0.45) NAPRTLMNAAKR1C3AKR1C2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-09-06 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225886-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NAPRT 2894/4885LMNA 1824/4885AKR1C3 463/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 NAPRT 2894/4885LMNA 1824/4885AKR1C3 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.